OGT SureSeq Myeloid MRD Panel

OGT, a Sysmex Group company, is launching the SureSeq Myeloid MRD Panel, claimed to represent a substantial improvement on conventional flow cytometry and qPCR methods of detecting measurable residual disease (MRD) in acute myeloid leukaemia (AML) samples. Developed in collaboration with cancer experts and in accordance with European LeukemiaNet (ELN) and National Comprehensive Cancer Network (NCCN) recommendations, the next-generation sequencing (NGS) panel provides high sensitivity and coverage uniformity in one rapid assay, offering a solution for assessing MRD in AML samples.

MRD is an important biomarker for AML, and one of the strongest independent assessments for prognosis, monitoring and treatment-response assessments. As such, MRD offers good value in guiding risk-adapted therapies in clinical trials. The panel has been tailored to meet the challenges of MRD detection in AML research.

By combining strong coverage uniformity with a focused, expert-led panel design, the panel has been developed to detect variants at frequencies as low as 0.05% allele frequency, with high performance even in challenging targets such as NPM1, CEBPA and FLT3 internal tandem duplications (ITDs). The streamlined SureSeq workflow will enable researchers to perform rapid, comprehensive MRD analysis of mutations in myeloid samples to inform the development of future therapeutic treatments.